Compendia Bioscience Announces Commercial Release and Availability of Oncomine(TM) Concepts Map
Share:
ANN ARBOR, Mich., June 5 -- Compendia Bioscience, Inc. today announced the release and immediate availability of Oncomine(TM) Concepts Map, a high-value product extension of Compendia's flagship product Oncomine(TM) Professional. Oncomine Concepts Map (OCM) combines nearly 7,000 Oncomine cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources.
The new technology uses gene sets as a common language to compare and link disparate biological concepts, as recently described in the journal Neoplasia. A second study published in Nature Genetics used Oncomine Concepts Map to analyze prostate cancer gene expression in the context of the other gene signatures available in OCM. The result was an important new model describing the progression of prostate cancer.
"Oncomine Concepts Map allows researchers to leverage gene expression data within the Oncomine application in a whole new way," said lead study author Scott Tomlins. "The technology provides unexpected insights and puts a coherent biological story around complex gene expression data."
Three major biotech and pharmaceutical companies have already committed to licensing Oncomine Concepts Map on top of their existing Oncomine licenses, and many additional companies are actively evaluating the technology.
"We are excited by the reception Oncomine Concepts Map has received from our existing and prospective customers," said Compendia's co-founder and Chief Science Officer Dan Rhodes. "I know from my personal experience with the technology how insightful and revealing the results can be. I look forward to our customers applying the technology to accelerate and improve cancer drug development."
Oncomine Concepts Map is licensed to commercial users as part of the Oncomine Concepts Edition and the Oncomine Enterprise Edition. Visit www.compendiabio.com/ for more information. An academic preview edition is available to academic and non-profit researchers at http://www.oncomine.org/.
About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes.
About Oncomine(TM)
Oncomine(TM) combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates rapid and reliable biomarker and therapeutic target discovery, validation, and prioritization.
CONTACT: Jane Krug of Compendia Bioscience, Inc., +1-504-561-9525, media@compendiabio.com
